GNE-502, an orally active and potent estrogen receptor (ER) degrader, is specifically designed for breast cancer research.

GNE-502, administered orally at doses of 10 and 100 mg/kg, demonstrates adequate oral bioavailability for evaluation in a WT MCF7 tumor xenograft mouse model. It exhibits dose-dependent tumor growth inhibition at 10 and 30 mg/kg and achieves tumor stasis at 100 mg/kg, indicative of its potential efficacy in cancer therapy. Dosage and administration details for pharmacokinetic analysis confirm its sufficient oral exposure for effectiveness in the specified model.